364 related articles for article (PubMed ID: 26070917)
1. U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Ning YM; Brave M; Maher VE; Zhang L; Tang S; Sridhara R; Kim G; Ibrahim A; Pazdur R
Oncologist; 2015 Aug; 20(8):960-6. PubMed ID: 26070917
[TBL] [Abstract][Full Text] [Related]
2. Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summary.
Ning YM; Pierce W; Maher VE; Karuri S; Tang SH; Chiu HJ; Palmby T; Zirkelbach JF; Marathe D; Mehrotra N; Liu Q; Ghosh D; Cottrell CL; Leighton J; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Nov; 19(22):6067-73. PubMed ID: 24141628
[TBL] [Abstract][Full Text] [Related]
3. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer.
Kim CS; Choi YD; Lee SE; Lee HM; Ueda T; Yonese J; Fukagai T; Chiong E; Lau W; Abhyankar S; Theeuwes A; Tombal B; Beer TM; Kimura G
Medicine (Baltimore); 2017 Jul; 96(27):e7223. PubMed ID: 28682871
[TBL] [Abstract][Full Text] [Related]
4. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
Beer TM; Armstrong AJ; Rathkopf D; Loriot Y; Sternberg CN; Higano CS; Iversen P; Evans CP; Kim CS; Kimura G; Miller K; Saad F; Bjartell AS; Borre M; Mulders P; Tammela TL; Parli T; Sari S; van Os S; Theeuwes A; Tombal B
Eur Urol; 2017 Feb; 71(2):151-154. PubMed ID: 27477525
[TBL] [Abstract][Full Text] [Related]
5. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B
Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332
[TBL] [Abstract][Full Text] [Related]
6. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
Maeda H; Saito A
Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
[TBL] [Abstract][Full Text] [Related]
7. US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
Heiss BL; Chang E; Gao X; Truong T; Brave MH; Bloomquist E; Shah A; Hamed S; Kraft J; Chiu HJ; Ricks TK; Tilley A; Pierce WF; Tang L; Abukhdeir A; Kalavar S; Philip R; Tang S; Pazdur R; Amiri-Kordestani L; Kluetz PG; Suzman DL
J Clin Oncol; 2024 May; 42(15):1851-1860. PubMed ID: 38452327
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
Graff JN; Baciarello G; Armstrong AJ; Higano CS; Iversen P; Flaig TW; Forer D; Parli T; Phung D; Tombal B; Beer TM; Sternberg CN
Ann Oncol; 2016 Feb; 27(2):286-94. PubMed ID: 26578735
[TBL] [Abstract][Full Text] [Related]
9. The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients.
Kim CS; Theeuwes A; Kwon DD; Choi YD; Chung BH; Lee HM; Lee KH; Lee SE
Investig Clin Urol; 2016 May; 57(3):174-83. PubMed ID: 27195316
[TBL] [Abstract][Full Text] [Related]
10. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
Loriot Y; Miller K; Sternberg CN; Fizazi K; De Bono JS; Chowdhury S; Higano CS; Noonberg S; Holmstrom S; Mansbach H; Perabo FG; Phung D; Ivanescu C; Skaltsa K; Beer TM; Tombal B
Lancet Oncol; 2015 May; 16(5):509-21. PubMed ID: 25888263
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Ning YM; Maher VE; Zhang L; Tang S; Ghosh D; Aziz R; Palmby T; Pfuma E; Zirkelbach JF; Mehrotra N; Tilley A; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Dec; 19(24):6650-6. PubMed ID: 24150234
[TBL] [Abstract][Full Text] [Related]
12. Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.
Alumkal JJ; Chowdhury S; Loriot Y; Sternberg CN; de Bono JS; Tombal B; Carles J; Flaig TW; Dorff TB; Phung D; Forer D; Noonberg SB; Mansbach H; Beer TM; Higano CS
Clin Genitourin Cancer; 2017 Oct; 15(5):610-617.e3. PubMed ID: 28344102
[TBL] [Abstract][Full Text] [Related]
13. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.
Sternberg CN; de Bono JS; Chi KN; Fizazi K; Mulders P; Cerbone L; Hirmand M; Forer D; Scher HI
Ann Oncol; 2014 Feb; 25(2):429-34. PubMed ID: 24478320
[TBL] [Abstract][Full Text] [Related]
14. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
Loriot Y; Fizazi K; de Bono JS; Forer D; Hirmand M; Scher HI
Cancer; 2017 Jan; 123(2):253-262. PubMed ID: 27648814
[TBL] [Abstract][Full Text] [Related]
15. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
Armstrong AJ; Lin P; Tombal B; Saad F; Higano CS; Joshua AM; Parli T; Rosbrook B; van Os S; Beer TM
Eur Urol; 2020 Sep; 78(3):347-357. PubMed ID: 32527692
[TBL] [Abstract][Full Text] [Related]
16. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
17. Enzalutamide in Japanese patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial.
Kimura G; Yonese J; Fukagai T; Kamba T; Nishimura K; Nozawa M; Mansbach H; Theeuwes A; Beer TM; Tombal B; Ueda T
Int J Urol; 2016 May; 23(5):395-403. PubMed ID: 27018069
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
Taplin ME; Armstrong AJ; Lin P; Krivoshik A; Phung D; Parli T; Tombal B; Beer TM
J Urol; 2017 Dec; 198(6):1324-1332. PubMed ID: 28736322
[TBL] [Abstract][Full Text] [Related]
20. Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study.
Pu YS; Ahn H; Han W; Huang SP; Wu HC; Ma L; Yamada S; Suga K; Xie LP
Adv Ther; 2022 Jun; 39(6):2641-2656. PubMed ID: 35397772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
